Medtronic, Inc. today announced CE (Conformité Européene) Mark for the 23 mm CoreValve Evolut(TM) R System for transcatheter aortic valve implantation (TAVI). The novel, self-expanding valve and 14FR equivalent delivery system offers new capabilities that  advance valve performance and deliverability during the procedure, while providing the option to recapture (re-sheath the valve back into the catheter) and reposition (move the valve to a new position either above or below its current placement) the valve during deployment phase, if needed.

Direct Flow Medical, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, today announced it has received the CE Mark (Conformité Européenne) for a 23mm sized valve as part of its Direct Flow Medical Transcatheter Aortic Valve System, expanding the patient population that can be treated with its technology. The company also announced receipt of the CE Mark for implantation of all of its valves without the use of contrast media, protecting patients from kidney injury during transcatheter aortic valve implantation (TAVI).

Torrance Memorial Medical Center and USC's Keck School of Medicine have announced an affiliation to expand heart surgery services at the medical center in Torrance.

Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes.

Frank F. Ing, MD, FAAP, FACC, FSCAI, associate chief of Cardiology and director of the Cardiac Catheterization Laboratory at Children’s Hospital Los Angeles, has taken on two new roles at CHLA: chief of the Division of Cardiology and co-director of the Heart Institute. Ing replaces Michael Silka, MD, who filled both positions for more than 15 years. Ing assumed his new responsibilities as of July 1.

Today, Texas Children's Heart Center is excited to announce the addition of two new members to its Adult Congenital Heart Disease Program team: pediatric and adult cardiologist, Dr. Peter Ermis, and pediatric and adult cardiologist, Dr. Wilson Lam. Texas Children's Heart Center is ranked #2 nationally in cardiology and heart surgery by U.S. News & World Report. For more information about the Adult Congenital Heart Disease Program at Texas Children's Hospital, visit the website.

Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation Lotus Valve System continued to demonstrate impressive performance at six months, according to new data presented at EuroPCR 2014 in Paris.

Medtronic, Inc. today revealed new data showing that patients treated with the CoreValve System experienced positive clinical outcomes in the rigorous "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR 2014, the transcatheter aortic valve implantation (TAVI) study revealed low rates of mortality and stroke, and showed exceptional valve performance through two years.